Page 38 - July-August 2020

Q BIOMED GETS $7.5M GRANT FOR GLAUCOMA

RESEARCH

Q BioMed Inc., a commercial that Q BioMed and Mannin, who that causes glaucoma – preclinical
stage biotech company informs that have been partners since 2015, can development of a small molecule
its technology partner, Mannin, led now fast-track the development pharmaceutical eye-drop as well
by President and CEO, Dr. George of these therapeutics. Denis Corin, as a novel recombinant protein
Nikopoulos, has received a $7.5M CEO of Q BioMed, said of the grant, injectable biologic. The company
grant from the German state of “We are thrilled that we will be able is also exploring other therapeutic
Saxony. Mannin is a research-stage to speed the development of these opportunities using these molecules
biotechnology company focused promising therapeutics and bring for vascular diseases.
on the discovery, development, and new innovation to glaucoma patients
commercialisation of therapeutics as soon as possible. Our partnership George Nikopoulos, President
for vascular diseases. with Mannin and now, the and CEO of Mannin, stated, “We are
government of Saxony is important very encouraged by the confidence
As per a press note, the to the advancement of this unique and enthusiasm the government of
main objective of the grant is to drug platform and we look forward Saxony has shown in our research,
fund the development of novel to supporting the build-out of the and we are committed to making
pharmaceuticals and biologic Mannin European headquarters in accelerated progress through their
treatments for glaucoma as this Leipzig.” investment.”
disease is still considered to be a
leading cause of blindness in Europe. Mannin is currently working Further details regarding the
on two distinct modes of action research program will be announced
The approval of the grant means to reduce the intraocular pressure later this year.

TRANSITIONS OPTICAL INTRODUCES VIRTUAL

TRY-ON INITIATIVE

Transitions Optical has is designed to allow users to convenient,” said Patience
introduced a new, Virtual Try- trial and play with Transitions Cook, director North America
On initiative for its Transitions Signature GEN 8 lenses in marketing, Transitions Optical.
Signature GEN 8 Lenses. different colours across the “By sharing the virtual try-on,
full range of activation tints. practices can pre-educate
The immersive augmented As users tap through different patients on Transitions Signature
reality experience enables lens colours and frame options, GEN 8 lenses before they visit
patients to see themselves in they are also able to capture their eyecare professional.
all seven Transitions Signature downloadable photos in all This is particularly important
GEN 8 lens colours and choose stages of tint. as many practices are seeking
from a selection of frame styles to minimise contact due to the
even before they enter the The Transitions lens COVID-19 situation.”
showroom. This customisable virtual try-on uses the best
digital experience also helps in class technology provided While using the virtual
users to access the virtual by FittingBox to give users a try-on users can also search for
try-on at Transitions.com/VTO realistic, interactive experience an eyecare professional near
on their own desktop, mobile or wearing Transitions lenses in them by clicking “Find Your
tablet devices – minimising auto-sized frames in real time. Transitions.”
the need for patient contact in
the practice. “It’s more important than The Virtual Try-on is currently
ever to make patients’ digital available in the U.S. and Canada
The unique technology journey customisable and on Transitions.com.

| JULY-AUG 2020 | 34 OPHTHALMIC NEWS